Oliver Kiddie – Managing Director – Legend Mining (ASX:LEG) is an Australian exploration company listed on the Australian Securities Exchange (ASX:LEG). Legend’s mission is to make value-adding mineral discoveries and utilise all available asset bases to maximise stakeholder benefit.
Copyright 2024 – Finance News Network
27 Nov 2020 - East 33 Limited (ASX:E33) Co-founder and Executive Chairman James Garton talks about the company's dominant position as a supplier and distributor of Sydney Rock Oysters, ambitions ahead of its listing on the ASX and the potential of the world-class Sydney Rock Oyster as a luxury food alongside French Champagne or Beluga Caviar.
05 Nov 2021 - BrainChip Holdings Limited (ASX:BRN) Vice President of Worldwide Sales and Marketing Rob Telson talks about the company and the future of artificial intelligence.
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
20 May 2021 - Complii FinTech Solutions Limited (ASX:CF1) Executive Chairman Craig Mason talks about how the company's digital platform provides an electronic centralised framework to manage AFSL-centric (Stockbroker/Financial Planner/Adviser) workflows for compliance, capital raising and operational efficiencies.
09 Sep 2024 - ABx Group Limited (ASX:ABX) Managing Director and CEO Dr Mark Cooksey discusses the significance of the company's memorandum of understanding with Ucore Rare Metals.
08 Jun 2021 - Danakali Limited (ASX:DKM) Executive Chairman Seamus Cornelius discusses the company's Colluli project, including financing and economics, and the positive impact of the project on the region.
04 Dec 2019 - DigitalX Limited (ASX:DCC) Executive Director Leigh Travers talks about the growing interest in blockchain solutions for real world problems and the company's new DigitalX Bitcoin Fund.
10 Mar 2020 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin talks about results from the company's lead drug candidate OPT-302, and new funding for further clinical development for wet AMD (age-related macular degeneration) and DME (diabetic macular degeneration).